Conferences - Results from #160

Viewing 161-180 of 11775 articles

ESMO 2024: Phase 2 Study of Futibatinib plus Pembrolizumab in Patients with Advanced/Metastatic Urothelial Carcinoma: Final Analysis of Efficacy and Safety

ESMO 2024: Preliminary Efficacy And Safety Of Disitamab Vedotin With Pembrolizumab In Treatment-Naive HER2-Expressing, Locally Advanced Or Metastatic Urothelial Carcinoma: RC48G001 Cohort C

ESMO 2024: UpFrontPSMA : A Randomized Phase II Study of Sequential 177Lu-PSMA-617 and Docetaxel versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor (SPLASH)

ESMO 2024: Radioligand Theranostics in Prostate Cancer: Status Quo and New Developments

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

ESMO 2024: Invited Discussant: ETER100, TACITO, and CheckMate 9ER Trials

ESMO 2024: EV-302: Exploratory Analysis of Nectin-4 Expression and Response to 1L Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

ESMO 2024: Anlotinib Combined with Anti-PD-L1 Antibody Benmelstobart (TQB2450) Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma -a Randomized, Open-Label, Phase III Study (ETER100)

ESMO 2024: Updates in Penile Cancer

ESMO 2024: ctDNA Clearance with Neoadjuvant Durvalumab + Tremelimumab + Enfortumab Vedotin for Cisplatin-Ineligible MIBC from the Safety Run-in Cohort of the Phase 3 VOLGA Trial

ESMO 2024: Non-Clear Cell RCC

ESMO 2024: CARE1 Pragmatic Clinical Trial - First Line Randomised Study Platform to Optimize Treatment in Patients with Metastatic Renal Cell Carcinoma

ESMO 2024: Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma vs Observation: Extended Follow-up DFS Results and Metastatic Disease Recurrence Distribution

ESMO 2024: Invited Discussant: Improving Outcomes of Localized Urothelial Cancer

ESMO 2024: T Cell Engagers in Prostate Cancer

ESMO 2024: DLL-3 Targeted Therapy for Neuroendocrine Prostate Cancer

ESMO 2024: Outcomes with Novel Combinations in Non-Clear Cell RCC: ORACLE Study

ESMO 2024: Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial – 3 Year Update

ESMO 2024: Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC Patients

4
5
6
7
8
9
10
11
12
13